David E Lanfear1, Sheryl Chow2, Badri Padhukasahasram2, Jia Li2, David Langholz2, W H Wilson Tang2, L Keoki Williams2, Hani N Sabbah2. 1. Advanced Heart Failure and Transplant Cardiology, Section, Cardiology Division, Department of Medicine, Henry Ford Hospital, Detroit, Michigan. Electronic address: dlanfea1@hfhs.org. 2. Advanced Heart Failure and Transplant Cardiology, Section, Cardiology Division, Department of Medicine, Henry Ford Hospital, Detroit, Michigan.
Abstract
BACKGROUND: Natriuretic peptides (NPs) represent a critical pathway in heart failure (HF). However, there is wide individual variability in NP system activity, which could be partly genetic in origin. We explored genetic and nongenetic contributions to B-type natriuretic peptide (BNP) inactivation. METHODS: Chronic HF patients (n = 95) received recombinant human BNP (nesiritide) at standard doses, and BNP levels were measured at baseline, after 2 hours of infusion, and 30 minutes after discontinuation. Genomic DNA was genotyped for 91 single-nucleotide polymorphisms (SNP) in 2 candidate genes. We tested the association of patient characteristics and genotype with 5 pharmacokinetics (PK) parameters: elimination rate constant, ΔBNP, BNP clearance, adjusted BNP clearance, and half-life. Linear regression with pleiotropic analysis was used to test genotype associations with PK. RESULTS: Participants' mean age was 63 years, 44% were female, and 46% were African American. PK parameters varied widely, some >10-fold. HF type (preserved vs reduced) was associated with PK (P < .01), whereas renal function, demographics, and body mass index and were not. Two SNPs in MME (rs989692, rs6798179) and 2 in NPR3 (rs6880564, rs2062708) also had associations with PK (P < .05). CONCLUSIONS: The pharmacokinetics of BNP varies greatly in HF patients, differs by HF type, and possibly by MME or NPR3 genotype. Additional study is warranted.
BACKGROUND: Natriuretic peptides (NPs) represent a critical pathway in heart failure (HF). However, there is wide individual variability in NP system activity, which could be partly genetic in origin. We explored genetic and nongenetic contributions to B-type natriuretic peptide (BNP) inactivation. METHODS:Chronic HFpatients (n = 95) received recombinant humanBNP (nesiritide) at standard doses, and BNP levels were measured at baseline, after 2 hours of infusion, and 30 minutes after discontinuation. Genomic DNA was genotyped for 91 single-nucleotide polymorphisms (SNP) in 2 candidate genes. We tested the association of patient characteristics and genotype with 5 pharmacokinetics (PK) parameters: elimination rate constant, ΔBNP, BNP clearance, adjusted BNP clearance, and half-life. Linear regression with pleiotropic analysis was used to test genotype associations with PK. RESULTS:Participants' mean age was 63 years, 44% were female, and 46% were African American. PK parameters varied widely, some >10-fold. HF type (preserved vs reduced) was associated with PK (P < .01), whereas renal function, demographics, and body mass index and were not. Two SNPs in MME (rs989692, rs6798179) and 2 in NPR3 (rs6880564, rs2062708) also had associations with PK (P < .05). CONCLUSIONS: The pharmacokinetics of BNP varies greatly in HF patients, differs by HF type, and possibly by MME or NPR3 genotype. Additional study is warranted.
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2011-12-15 Impact factor: 29.690
Authors: W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: Valentina Cannone; Brenda K Huntley; Timothy M Olson; Denise M Heublein; Christopher G Scott; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett Journal: Hypertension Date: 2013-09-16 Impact factor: 10.190
Authors: Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough Journal: N Engl J Med Date: 2002-07-18 Impact factor: 91.245
Authors: Naveen L Pereira; Dong Lin; Linda Pelleymounter; Irene Moon; Gail Stilling; Bruce W Eckloff; Eric D Wieben; Margaret M Redfield; John C Burnett; Vivien C Yee; Richard M Weinshilboum Journal: Circ Cardiovasc Genet Date: 2013-03-14
Authors: Alan H B Wu; Milton Packer; Andrew Smith; Rachel Bijou; Daniel Fink; Johannes Mair; Lars Wallentin; Nina Johnston; Carolyn S Feldcamp; Doris M Haverstick; Charaf E Ahnadi; Andrew Grant; Normand Despres; Barry Bluestein; Farooq Ghani Journal: Clin Chem Date: 2004-03-09 Impact factor: 8.327
Authors: David E Lanfear; Jia Li; Raza Abbas; Ricoung She; Badri Padhukasahasram; Ramesh C Gupta; David Langholz; W H Wilson Tang; L Keoki Williams; Hani N Sabbah; Sheryl L Chow Journal: J Cardiovasc Transl Res Date: 2015-11-20 Impact factor: 4.132
Authors: Milton Packer; Carolyn S P Lam; Lars H Lund; Mathew S Maurer; Barry A Borlaug Journal: Eur J Heart Fail Date: 2020-06-26 Impact factor: 15.534